Journey Medical said on Monday the U.S. Food and Drug Administration has approved its drug for the treatment of a long-term skin condition called rosacea, sending the company's shares up more than 13% before the bell.

The US’ Food and Drug Administration (FDA) has approved Journey Medical’s Emrosi, the brand name for its 40mg minocycline hydrochloride extended-release capsules, to be used in the treatment of dermatological condition rosacea.

Journey Medical has claimed FDA approval for its Emrosi therapy for rosacea, which it thinks could become a "standard of care" drug for the common skin disorder.

Journey Medical (NASDAQ:DERM) has received FDA approval for its drug Emrosi for the treatment of rosacea. Emrosi is the brand name for minocycline hydrochloride extended release 40 mg capsules. The product was developed with Dr.